Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.17), $0.12 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $31.43 million versus the consensus estimate of $32.75 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.